David Parrot insider trades

Open-market stock purchases and sales by David Parrot, Chief Financial Officer at Scribe Therapeutics, Inc, from SEC Form 4 filings since Mar 13, 2026.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +36%.

Recent trades

DateStockTradeValue
Jul 23, 2026SCTX Scribe Therapeutics, IncBought (not open market)—
Jul 23, 2026SCTX Scribe Therapeutics, IncBought$20K
Mar 13, 2026SCTX Scribe Therapeutics, IncBought (not open market)—

Companies traded

  • SCTX Scribe Therapeutics, Inc: 1 buy, last Jul 23, 2026

Get free alerts when David Parrot files a new trade →